Beta-Thalassemia — Deal Benchmarks & Valuation
Market Analysis
Beta-Thalassemia is one of the most actively transacted indications in rare disease licensing. Phase 2 deals for beta-thalassemia carry a median total deal value of $1.9B, with upfront payments ranging from $171M to $536M. The recommended deal structure allocates approximately 18% to upfront payments and 82% to milestones.
Milestone structures for beta-thalassemia deals allocate $351M to development milestones, $399M to regulatory milestones, and $845M to commercial milestones. Royalty rates range from 8.3% to 16.7% at the base tier, with tiered escalation reaching 12.3%-20.7% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for beta-thalassemia licensing?
What royalty rates are standard for beta-thalassemia deals?
How are beta-thalassemia deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.